课题基金 / 基金详情

COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism

COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
COBRRA 试验:利伐沙班和阿哌沙班治疗急性静脉血栓栓塞的出血风险比较
批准号:
478040
负责人:
Castellucci Lana
金额:
$46.26万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2023
资助国家:
加拿大
项目状态:
未结题
起止时间:
2023-03-01 至 2025-03-01

项目摘要

项目成果

Castellucci Lana的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Lay Abstract: The presence of new blood clots in the veins of legs and lungs decreases the quality of life of patients and may cause death. After the first clot, patients have higher chances of developing new clots and this increases the possibility of de
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
  • 批准号:
    450705
  • 项目类别:
    Operating Grants
  • 资助金额:
    $161.06万
  • 财政年份:
    2021
  • 负责人:
    Castellucci Lana
  • 依托单位:
Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
  • 批准号:
    432966
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2020
  • 负责人:
    Castellucci Lana
  • 依托单位:
Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial
海外基金